Published in Hepatitis Weekly, March 4th, 2002
The latest of such studies has shown tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2 ligand (Apo2L)) gene therapy is effective in hepatocellular carcinoma (HCC), a primary form of liver cancer often resulting from cirrhosis, exposure to liver toxins, viral hepatitis, or other risk factors.
A new study conducted by Y. Yamashita and coauthors, Kyushu University, Japan, has revealed important information about the effects of TRAIL/Apo2L on HCC in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.